After treatment with tested substances in multi-well plates, high content screening (HCS) or automated microscope-based screening detects biological activity in cells or entire organisms. Various methods for analyzing whole cells or cell components are included in the high content screening. Typically, one or more fluorescent dyes are used to measure several aspects of the cell or organism. Our High Content Screening (HCS) scientists have access to the Image Xpress Ultra from Molecular Devices Corporation in addition to the CellInsight CX5 platform we developed in-house. These tools can be used to perform a variety of assays, as indicated in the examples below.
Based on the degree of staining within the nucleus, this assay uses a nuclear strain to detect the cell cycle position of each cell. It can be employed in assays for cell viability, apoptosis, and mitosis.
We can make inferences about the biological implications of translocation of these molecules in the cell by establishing the location of a receptor, protein, or molecule of interest in treated.
Cell movement induce a localized rise in fluorescent protein content. It can be detected using this kind of investigation. Highly luminous granules reveal the concentration of tis protein.
This assay determines the condition of each cell using many wave lengths. Then scores each wave length against other wave lengths relying on size, shape, and position.
The CellInsight CX5 HCS Platform uses property auto focus and united plate examine intelligence technique to examine cell populations and pheno types.
The Ultra is a real point scan meeting micro scope that captures images at a higher resolve than the Micro xpress. It include four solid state lasers with feeling rate.
High content showing covers a range of techniques for study whole cells or their element parts. Usually, more bright dyes are used to test a variety of properties. Causing the display of multiple limits all at once.
Comfortable with Any Model
Any Target, Any Label
Images Into Insights
Confocal and widefield
We offer assay development, filter, and data analysis knowledge and services. For high content screens the readout is based on images. Our High Content Screening (HCS) is helpful for your business boost.
Our team can assist you choose the proper cell type and assay settings. Their important experience in high ability masking. In-house image analysis method design, and disease biology.
HCA has advanced to include multi cell structures. 3D globes and cultures, as well as multiple to monitor various features within a micro environment in a single well.
High resolution imaging is a potent tool for drug development, but its achievement requires special tackle and knowledge that only a few companies have on hand.
We provides a complete range of High Content Screening (HCS) services to clients using 3D cell models and classic cell place assays, as experts in High Content Imaging and meeting tiny, in our assays, and 3D cell culture models. Our team of professionals at Eicra is here to guide your team through every stage of the high content viewing process. Our team is highly supple in how we work with clients, supply a wide menu of accepted in vitro covering services as well as speedy custom assay creation (3-4 week turn around time).
No client is too big or too little for us. We provide target support, bespoke assay creation, and end to end combine cover services. We also assist major cure companies in the structure of high content covering work flows. Specific image processing pipe lines for on-site use in larger covering operations.
We get together widely with our clients to define a adventures specific conditions. We offer small scale proof of concept work for unique projects to prove our skills and give you peace of mind that your screening campaigns are in excellent hands. To discuss your HCS needs, please contact us directly. You can utilize high content screening to monitor compounds in complicated cellular systems to forecast translational success as you progress your candidate through lead optimization.
Over the last five years, the use of 3D cell culture models in drug cover has risen at an digital rate. We understand the value of 3D cell culture because of its better in vivo application and affordable cost. 3D cell culture is rapidly progress and changing as a excess of models, lines, media, and matrices are embraced across the industry, each with its own set of benefits and limits.
From microtissues to prostate biopsies, rabbit retinas, and complete owl brains, our team of professionals has worked on a wide range of projects. We’ve created a reliable process for optimizing and validating new targets, and when combined with our expertise in high-resolution imaging, we can quantify almost any target with almost any label.
Drug development is a fast-paced process, and high-content screening was designed to keep up. The data management process is relatable to the high content screening. To speed up high-content screening, our team employs automation, computerization, and robotics. Three to four weeks is a typical turnaround time for three-color assays. Before moving on to larger screens for specific projects, we start with a low-cost proof of concept to demonstrate our competence.
A typical HCS test can potentially generate over 100,000 pictures, creating a significant bottleneck in data processing and analysis. We quickly filter through tens of thousands of photos to extract quantitative data, collecting cell counts, morphological features, label colocalization, and performing statistical comparisons across groups using our custom-built image processing pipeline.
In high content screening (HCS), cells are first incubated with the material, then their structures and molecular components are examined after a period of time. The most popular method includes marking proteins with fluorescent tags, followed by automated picture processing to measure changes in cell phenotypic.
Negative drug testing findings of high content screening will take around 24 hours to arrive at the laboratory, while non-negative results will take an additional 24-72 hours (due to additional confirmation). If non-negative findings are provided through the Medical Review procedure, the MRO will need to call the donor and confirm the outcome for a further 24-72 hours.